New office accommodates higher headcount reflecting rapid growth for both companies
Partners4Access (P4A), the global specialists in orphan drug access and Global Pricing Innovations (GPI), the pricing experts have moved their London headquarters to 120 New Cavendish Street.
Both P4A and GPI have seen a rapid expansion in their client base throughout 2017. The larger offices accommodate the growth in headcount and functions required to meet the needs of new clients and deliverables. In addition, 120 New Cavendish Street is a central London location and so further enhances P4A and GPI’s access to talent and pharma industry clients.
“The P4A team has grown substantially following a stellar business performance in 2017. The new office allows for our continued and steady growth trajectory,” said Sophie Schmitz, Managing Partner of P4A.
Preeti Patel, Founder and CEO for GPI added: ” We have rapidly expanded with both new clients and novel improvements to our services. Our new offices allow us to both accommodate our recently expanded team and cater for future additions required to support our growth.”
P4A and GPI entered into a strategic collaboration in 2016 to offer integrated price and access solutions for the pharmaceutical industry. The growth and expansion is a clear success indicator of the consolidated client services of the two companies.
We are specialists in orphan drug access, partnering with our clients to achieve launch success worldwide. Through our initiatives, we are able to inform and shape the conversation of orphan drugs. Our expert team is specialised in several key areas to optimize price and access potential. Our focus areas include: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence. As one of the only consultancies with comprehensive experience in cell and gene therapies, we are excellently placed to help you with your commercialization plans.
At P4A, we believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers. For more information, please email P4A at [email protected].
GPI supports pricing decisions and strategies through a combination of robust data-driven insights and bespoke analytical solutions, helping companies achieve operational improvement and market access excellence. GPI tools and services optimizes clients’ price and value understanding for pre-and post-launch decision making.
As a global company, GPI has operating units and service partners throughout the world. GPI (www.globalpricing.com) is a privately held company headquartered in London, UK. For more information contact GPI at [email protected]